Skip to content
No results
  • Home
  • Pharmacies and Hospitals
  • pharmaceutical-wholesaler
  • Oncology Diseases
  • Products
  • Articles
    • News
    • Blog
    • QA
    • Patient Guide
  • About Us
  • Contact

Hello, feel free to inquire - up to 50% OFF!

dengyuemed logo
China Medicine Wholesaler
  • Home
  • Pharmacies and Hospitals
  • pharmaceutical-wholesaler
  • Oncology Diseases
  • Products
  • Articles
    • News
    • Blog
    • QA
    • Patient Guide
  • About Us
  • Contact
dengyuemed logo
China Medicine Wholesaler
innovative pnh drug licancopan approved in china oral cfb inhibitor for dual hemolysis control
News

Innovative PNH Drug Licancopan Approved in China: Oral CFB Inhibitor for Dual Hemolysis Control

DengYueMed, DengYue 22/08/2026
anflekitug approved in china a new il-1β targeted treatment option for acute gouty arthritis
News

Anflekitug Approved in China: A New IL-1β Targeted Treatment Option for Acute Gouty Arthritis

DengYueMed, DengYue 21/08/2026
felzartamab approved for multiple myeloma, another cd38 monoclonal antibody enters the chinese market
News

Felzartamab Approved for Multiple Myeloma: Another CD38 Monoclonal Antibody Enters the Chinese Market

DengYueMed, DengYue 14/08/2026
tinengotinib approved for cholangiocarcinoma in china, addressing fgfr inhibitor resistance
News

Tinengotinib Approved for Cholangiocarcinoma in China, Addressing FGFR Inhibitor Resistance

DengYueMed, DengYue 13/08/2026
recibokibart approved for gpp china developed il 36r monoclonal antibody for generalized pustular psoriasis
News

Recibokibart Approved for GPP: China-Developed IL-36R Antibody Brings a New Treatment Option for Generalized Pustular Psoriasis

DengYueMed, DengYue 04/08/2026
insulin sudelidec approved for type 2 diabetes in china as a new chinese innovation in the long-acting basal insulin market
News

Insulin Sudelidec Approved for Type 2 Diabetes in China: A New Chinese Innovation in the Long-Acting Basal Insulin Market

DengYueMed, DengYue 30/07/2026
plozasiran now available in china for familial chylomicronemia syndrome treatment
News

Plozasiran Now Available in China: A Once-Every-3-Month siRNA Therapy for Familial Chylomicronemia Syndrome (FCS)

DengYueMed, DengYue 28/07/2026
ciprocopan approved in china
News

Ciprocopan Approved in China as the World’s First Once-Daily Oral CFB Inhibitor for PNH

DengYueMed, DengYue 23/07/2026
oveporexton approved first in china for type 1 narcolepsy treatment
News

Oveporexton Approved First in China: The First OX2R Agonist Targeting the Underlying Mechanism of Type 1 Narcolepsy

DengYueMed, DengYue 22/07/2026
the first approved adc for esophageal squamous cell carcinoma
News

The First Approved ADC for Esophageal Squamous Cell Carcinoma (ESCC): How Izalontamab Brengitecan Is Transforming Treatment

DengYueMed, DengYue 21/07/2026
adamgammadex sodium approved by nmpa as the world's second and china's first homegrown targeted neuromuscular block reversal agent
News

Adamgammadex Sodium Approved by NMPA: The World’s Second and China’s First Homegrown Targeted Neuromuscular Block Reversal Agent

DengYueMed, DengYue 17/07/2026
octahydroaminoacridine succinate approved in china for alzheimer's disease
News

Octahydroaminoacridine Succinate Approved in China for Alzheimer’s Disease, Marking Progress in Innovative Drug Development

DengYueMed, DengYue 16/07/2026
Quick Links
  • Home
  • Pharmacies and Hospitals
  • pharmaceutical-wholesaler
  • Oncology Diseases
  • Products
  • Articles
    • News
    • Blog
    • QA
    • Patient Guide
  • About Us
  • Contact
  • Home
  • Pharmacies and Hospitals
  • pharmaceutical-wholesaler
  • Oncology Diseases
  • Products
  • Articles
    • News
    • Blog
    • QA
    • Patient Guide
  • About Us
  • Contact
Get In Touch
  • Phone: +852-56986617
  • Whats APP: +852-56986617
  • Fax: +852-56986617
  • Email: inquiry@dengyuemed.com
  • Address: 6/F, Tai Tak Industrial Building, New Territories, Hong Kong
X-twitter Facebook Youtube Linkedin Instagram

Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights

WhatsApp us